Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial

This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA
Autori principali: Kazi, Dhruv S., Penko, Joanne, Coxson, Pamela G., Moran, Andrew E., Ollendorf, Daniel A., Tice, Jeffrey A., Bibbins-Domingo, Kirsten
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2017
Soggetti:
Research Letter
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5817484/
https://ncbi.nlm.nih.gov/pubmed/28829863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2017.9924
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi